Improving Treatment Outcomes of Patients With Waldenstrom Macroglobulinemia is organized by i3 Health.
Release: May 13, 2019
Expiration: May 12, 2020
Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with WM
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
Continuing Nursing Education:
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
Statement of Need:
Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal IgM. With an estimated 1,500 new cases reported in the United States annually, the malignancy accounts for 2% of non-Hodgkin lymphomas. Unfortunately, WM is considered incurable with available therapies. Patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, whereas those with high-risk disease have a 5-year survival rate of only 36%.
Upon completion of this activity, participants should be able to:
• Assess factors to risk stratify patients with WM
• Differentiate emerging efficacy and safety data on novel therapeutic approaches for treatment-naive and relapsed/refractory WM
• Apply strategies to monitor and manage adverse events associated with novel therapies for WM
Hematopathology, Hematology Blood and Marrow Transplant, Oncology